Abstract
Acetylcholine (ACh) is synthesized by choline acetyltransferase (ChAT) from acetylcoenzime A and choline. This reaction occurs not only in pre-ganglionic fibers of the autonomic nervous system and post-ganglionic parasympathetic nervous fibers but also in non neuronal cells. This knowledge led to expand the role of ACh as a neurotransmitter and to consider it as a “cytotransmitter” and also to evaluate the existence of a non-neuronal cholinergic system comprising ACh, ChAT, acetylcholinesterase, and the nicotinic and muscarinic ACh receptors, outside the nervous system. This review analyzes the participation of cholinergic system in inflammation and discusses the role of different muscarinic and nicotinic drugs that are being used to treat skin inflammatory disorders, asthma, and chronic obstructive pulmonary disease as well as, intestinal inflammation and systemic inflammatory diseases, among others, to assess the potential application of these compounds as therapeutic tools.
Keywords: acetylcholine, muscarinic receptors-nicotinic receptors-cholinergic drugs, atopic dermatitis-chronic obstructive pulmonary disease, intestinal inflammation, sepsis.
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title:Cholinergic Drugs as Therapeutic Tools in Inflammatory Diseases: Participation of Neuronal and Non-Neuronal Cholinergic Systems.
Volume: 12 Issue: 2
Author(s): María Elena Sales
Affiliation:
Keywords: acetylcholine, muscarinic receptors-nicotinic receptors-cholinergic drugs, atopic dermatitis-chronic obstructive pulmonary disease, intestinal inflammation, sepsis.
Abstract: Acetylcholine (ACh) is synthesized by choline acetyltransferase (ChAT) from acetylcoenzime A and choline. This reaction occurs not only in pre-ganglionic fibers of the autonomic nervous system and post-ganglionic parasympathetic nervous fibers but also in non neuronal cells. This knowledge led to expand the role of ACh as a neurotransmitter and to consider it as a “cytotransmitter” and also to evaluate the existence of a non-neuronal cholinergic system comprising ACh, ChAT, acetylcholinesterase, and the nicotinic and muscarinic ACh receptors, outside the nervous system. This review analyzes the participation of cholinergic system in inflammation and discusses the role of different muscarinic and nicotinic drugs that are being used to treat skin inflammatory disorders, asthma, and chronic obstructive pulmonary disease as well as, intestinal inflammation and systemic inflammatory diseases, among others, to assess the potential application of these compounds as therapeutic tools.
Export Options
About this article
Cite this article as:
Elena Sales María, Cholinergic Drugs as Therapeutic Tools in Inflammatory Diseases: Participation of Neuronal and Non-Neuronal Cholinergic Systems., Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2013; 12 (2) . https://dx.doi.org/10.2174/1871523011312020002
DOI https://dx.doi.org/10.2174/1871523011312020002 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hydroxamic Acids as Pharmacological Agents: An Update
Medicinal Chemistry Reviews - Online (Discontinued) Catalytic DNA: A Novel Tool for Gene Suppression
Current Drug Targets The Effects of Vitamin B in Depression
Current Medicinal Chemistry Hepatobiliary Diseases and Insulin Resistance
Current Medicinal Chemistry When Cells Become a Drug. Endothelial Progenitor Cells for Cardiovascular Therapy: Aims and Reality
Recent Patents on Cardiovascular Drug Discovery Molecular Mechanisms of Inflammation. Anti-Inflammatory Benefits of Virgin Olive Oil and the Phenolic Compound Oleocanthal
Current Pharmaceutical Design Desmopressin 30 Years in Clinical Use: A Safety Review
Current Drug Safety Substance-Related Disorders and Somatic Symptoms: How Should Clinicians Understand the Associations?
Current Drug Abuse Reviews Angiogenesis-regulating microRNAs and Ischemic Stroke
Current Vascular Pharmacology Preventing and Treating Anthracycline-Related Cardiotoxicity in Survivors of Childhood Cancer
Current Cancer Therapy Reviews Intranasal Drug Delivery to the Central Nervous System: Present Status and Future Outlook
Current Pharmaceutical Design Protease-Activated Receptors (PARs) are Partly Pro-Inflammatory and Partly Anti-Inflammatory: Will PAR Agonists or Antagonists Participate in Future Drug Therapies?
Current Drug Targets The Role of Streptokinase as a Virulence Determinant of Streptococcus pyogenes – Potential for Therapeutic Targeting
Current Drug Targets Targeted Delivery of Anti-Inflammatory Agents to Tumors
Current Pharmaceutical Design Cutoff Values of D-Dimer and FDP in Plasma for the Diagnosis of Thrombosis
Vascular Disease Prevention (Discontinued) Erythropoietin Signaling and Neuroprotection
Current Signal Transduction Therapy Role of Lysophosphatidylcholine (LPC) in Atherosclerosis
Current Medicinal Chemistry Platelet Turnover in Atherothrombotic Disease
Current Pharmaceutical Design The Promise of Slow Down Ageing May Come from Curcumin
Current Pharmaceutical Design Percutaneous Valve Interventions
Current Cardiology Reviews